$CGEN

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

Compugen (CGEN) delivered earnings and revenue surprises of -33.33% and 38.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published May 19, 2025, 3:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 20, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates — source image
Decision brief

The 30-second read

$CGENNeutralLow
01

Why it matters

Earnings miss may lead to short-term price declines; revenue growth suggests potential for future recovery.

02

Market read

The news is highly relevant for traders focusing on biotech stocks, especially CGEN, with potential short-term volatility.

03

What to watch

Broader market trends and upcoming catalysts could influence stock movement beyond earnings results.

Timing: short-term (next few days)

Background

Compugen is a biotech company reporting Q1 2025 earnings, with notable revenue growth but significant earnings miss.

Company-level read

Ticker impact

$CGENNeutralMedium confidence
Context

The news directly pertains to Compugen's recent quarterly earnings report, making it highly relevant for short-term trading decisions.

Expected impact

Potential short-term decline followed by stabilization or slight rebound as investors digest the mixed results.

Evidence & confidence

Earnings misses typically exert downward pressure, but strong revenue growth can mitigate negative sentiment. The net effect depends on investor perception and broader market conditions.

Market effects

Potential cautiousness in biotech and life sciences sectors due to earnings volatility.

Limited regional impact; primarily affects US-based biotech stocks.

Minimal; specific to US biotech sector.

Counterpoint

The revenue beat indicates underlying strength; the stock may rebound after initial sell-off.

Key entities

  • Compugen Ltd.

    Biotech firm focused on immuno-oncology and other therapeutic areas.

Related articles

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.